Rheumatoid arthritis

• Comparing the effectiveness of tofacitinib extended release (XR) chronotherapy, morning versus evening dosing, in rheumatoid arthritis (RA) … Recruiting
  2024-517865-17-01 6 2024-09-30 "Rheumatoid arthritis or psoriatic arthritis according to res"
• Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-Guided Dose Reduction in Patients with Rheumatoid Arthriti … Recruiting
  2023-506638-59-01 6 2024-01-09
• The 3TR Molecular Pathobiology-Driven Precision Therapy in RA (3TR Precis-The-RA) study Recruiting
  2022-502021-18-00 6 2023-10-12 "Rheumatoid Arthritis"
• Utvärdering av två kortison behandlingsstrategier hos patienter med nydiagnostiserad, tidigare obehandlad reumatoid artrit: en randomiserad, … Recruiting
  2024-518775-54-00 6 2021-10-05
• Study of clinical response, MRI progression, synovitis and changes in gene expression profiles in response to Sarilumab in patients with rhe … Recruiting
  2024-514201-61-00 6 2019-12-10
• SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Recruitment ended
  2025-521791-63-00 4 2025-12-18 "Moderately to Severely Active Rheumatologic Disease"
• Phase IIa Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of FBL-MTX in Patients with Rheumatoid Arthritis Recruitment ended
  2023-510258-17-00 4 2024-07-24 "Rheumatoid arthritis (RA)"
• A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib V … Recruitment ended
  2022-502578-18-00 11 2023-11-07 "Rheumatoid Arthritis"
• Inhibition of JAK enzymes in early stage joint inflammation Recruitment ended
  2024-514026-23-00 4 2023-09-06 "preclinical phase of rheumatoid arthritis"
• Efficacy of Abatacept vs Adalimumab in Early, Autoantibody positive Rheumatoid Arthritis (RA) and who did not respond well to methotrexate. Recruitment ended
  2023-506450-20-00 5 2021-11-05 "Rheumatoid Arthritis"
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Meth … Recruitment ended
  2022-501017-31-00 5 2016-05-10
• A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases (Breakfree-1) Halted
  2023-503823-24-01 3 2024-04-15 "Systemic Sclerosis"
• A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in … Ended
  2024-510826-16-00 5 2025-04-07 "Rheumatoid Arthritis"
• A clinical study of MK-2420 in healthy people (MK-2420-002) Ended
  2024-516548-25-00 3 2025-03-12
• A clinical study of MK-2420 in healthy men (MK-2420-003) Ended
  2024-518104-47-00 3 2024-12-19
• A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in … Ended
  2024-510945-32-00 5 2024-12-17
• A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi … Ended
  2023-506664-14-00 5 2024-10-24 "Rheumatoid Arthritis"
• RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHAR … Ended
  2023-510247-38-00 3 2024-06-07
• MK-2420 SAD Study Ended
  2024-511297-73-00 1 2024-05-03
• A placebo-controlled safety and tolerability study of intravenous (IV) and subcutaneous (SC) AZD1163 in healthy volunteers Ended
  2023-509574-34-00 1 2024-04-10 "Rheumatoid Arthritis"
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to … Ended
  2023-504564-42-00 4 2024-04-08 "Moderate to Severe Rheumatoid Arthritis"
• A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended
  2023-503910-60-00 4 2024-03-05
• A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by t … Ended
  2023-508030-33-00 8 2024-03-01 "Healthy volunteers"
• A RANDOMIZED, DOUBLE-BLIND, THREE-PART, TWO-PERIOD, TWO-SEQUENCE, SINGLE-DOSE, CROSS-OVER STUDY TO COMPARE THE PHARMACOKINETICS (PK), SAFETY … Ended
  2023-507877-17-00 2 2024-02-12 "Not applicable, Healthy Volunteers"

Showing 25–48 of 55 trials